§ 01 Overview
Overview
Long-acting amylin analog that slows gastric emptying and enhances satiety, typically paired with semaglutide (CagriSema).
Phase II monotherapy and CagriSema Phase III (REDEFINE) reported in 2024–2025 with ~22% weight loss in key arms.
§ 02 Mechanism
Mechanism of action
Cagrilintide is an acylated amylin analog with extended half-life. It acts on amylin and calcitonin receptors to slow gastric emptying, suppress glucagon, and increase satiety via area postrema signaling.
- 01Additive weight loss when combined with GLP-1 agonists
- 02Reduced food cravings and portion size
- 03Preserved lean mass in some trials
§ 03 Dosing
Dosing protocol
Standard Protocol
- Dose Range
- 0.16 – 2.4 mg weekly
- Route
- SubQ
- Frequency
- Weekly
- Cycle
- Titrate alongside GLP-1 if stacked.
§ 04 Evidence
Evidence & research
Phase II monotherapy and CagriSema Phase III (REDEFINE) reported in 2024–2025 with ~22% weight loss in key arms.
FDA Status
Investigational as monotherapy; CagriSema in Phase III.
§ 05 Stacks
Common stacks
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
Retatrutide + Cagrilintide: The STRONGEST Appetite Suppression Stack?! Western Hockey League (9npK322UPQ) - Fathom Journal
Retatrutide + Cagrilintide: The STRONGEST Appetite Suppression Stack?! Western Hockey League (9npK322UPQ) Fathom Journal
Novo Nordisk Tests Cagrilintide in Patients Who Cannot Tolerate GLP-1 Weight-Loss Drugs - TipRanks
Novo Nordisk Tests Cagrilintide in Patients Who Cannot Tolerate GLP-1 Weight-Loss Drugs TipRanks
Cagrilintide-Semaglutide Could Improve Glycemic Control in Type 2 Diabetes Patients Taking Basal Insulin - Docwire News
Cagrilintide-Semaglutide Could Improve Glycemic Control in Type 2 Diabetes Patients Taking Basal Insulin Docwire News
Once-Weekly Cagrilintide Plus Semaglutide Promising in T2D - Gastroenterology Advisor
Once-Weekly Cagrilintide Plus Semaglutide Promising in T2D Gastroenterology Advisor
Cellular loci for cagrilintide action identified - Nature
Cellular loci for cagrilintide action identified Nature
A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance - Nature
A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance Nature
Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study - The Lancet
Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study The Lancet
Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study - The Lancet
Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study The Lancet
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
International · 1
Trident Peptides
1,299+ Trustpilot reviews (5-star). Strongest review base in UK research peptides. No visible ISO/GMP; COAs not posted.
Research-use-only · 2
Swiss Chems
Established SARMs/peptide vendor. FDA warning letter Dec 2024 for GLP-1s. Weaker peptide QC than SARMs QC.
Summit Research
FDA warning letter December 2024 across multiple GLP-1s.
Listings are informational, not endorsement. Verify credentials and flags against FDA and PCAB databases before purchasing. Full directory & how to verify →
§ 09 Safety
Safety & side effects
Side effects
- 01Nausea
- 02Appetite suppression can be substantial
Contraindications
None specified.
§ 10 Questions
Cagrilintide FAQ
- What is Cagrilintide?
- Long-acting amylin analog that slows gastric emptying and enhances satiety, typically paired with semaglutide (CagriSema). Cagrilintide is an acylated amylin analog with extended half-life. It acts on amylin and calcitonin receptors to slow gastric emptying, suppress glucagon, and increase satiety via area postrema signaling.
- What is Cagrilintide used for?
- Reported uses include additive weight loss when combined with glp-1 agonists, reduced food cravings and portion size, and preserved lean mass in some trials. Evidence strength is rated Clinical — see the evidence section for detail.
- How is Cagrilintide dosed?
- Commonly referenced dosing is 0.16 – 2.4 mg weekly, administered SubQ. This is educational reference only; consult a licensed clinician before use.
- What are the side effects of Cagrilintide?
- Commonly reported side effects include nausea and appetite suppression can be substantial. This list is not exhaustive.
- Is Cagrilintide legal?
- Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk. FDA status: Investigational as monotherapy; CagriSema in Phase III..